SEHK:175
SEHK:175Auto

Does Geely Still Offer Value After Recent Volatility in China’s EV Market?

Wondering if Geely Automobile Holdings is actually good value at today’s price, or if the market has already driven off with the easy gains? This breakdown is designed to give you a clear, no-jargon answer. Despite a choppy ride in the short term, with the share price down 6.3% over the last week and 3.7% over the last month, the stock is still up 17.6% year to date and 7.6% over the last year. It has delivered 52.9% over three years but lost 23.0% across five years. Recent headlines around...
SEHK:628
SEHK:628Diversified Financial

Asian Market Insights: Ever Sunshine Services Group And 2 Other Promising Penny Stocks

As global markets navigate a landscape of interest rate adjustments and economic uncertainties, Asia's financial scene continues to capture attention with its diverse investment opportunities. Penny stocks, while often overlooked, represent a unique segment where smaller or newer companies can offer significant growth potential at lower price points. In this article, we explore several promising penny stocks in Asia that combine solid financial health with the potential for impressive returns.
SEHK:2228
SEHK:2228Life Sciences

Assessing XtalPi Holdings (SEHK:2228) Valuation After New AI–Genomics Cancer Detection Partnership

XtalPi Holdings (SEHK:2228) just signed a two year memorandum of understanding with Mirxes Holding, aiming to fuse Mirxes genomics database with XtalPi's AI plus robotics platform for earlier gastrointestinal cancer detection and intervention. See our latest analysis for XtalPi Holdings. The MOU lands at an interesting moment, with XtalPi’s share price at HK$9.26 after a weak 1 month share price return but still a strong year to date share price return and solid 1 year total shareholder...
SEHK:9926
SEHK:9926Biotechs

The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial

Akeso has recently reported a series of oncology milestones, including FDA approval to start a global Phase III trial of cadonilimab in advanced HER2‑negative gastric cancer and new Phase II/III data on ivonescimab in triple‑negative breast cancer and squamous non‑small cell lung cancer. Together, these updates underscore Akeso’s push to position its bispecific antibodies as potential new standards of care across multiple solid tumors, supported by both efficacy and quality‑of‑life...
SEHK:992
SEHK:992Tech

Lenovo (SEHK:992) Valuation Check After Major AI-Focused Data Infrastructure Launch

Lenovo Group (SEHK:992) just rolled out a sweeping lineup of AI ready storage, virtualization, and data management offerings, a strategic push that could gradually reshape how investors view its infrastructure and services growth story. See our latest analysis for Lenovo Group. Against that backdrop, Lenovo’s HK$9.66 share price reflects a mixed year, with recent share price returns under pressure but a solid 1 year total shareholder return of about 9.8 percent and strong three year...
SEHK:2367
SEHK:2367Personal Products

Did Giant Biogene’s New Buyback Plan Just Shift Giant Biogene Holding's (SEHK:2367) Investment Narrative?

Earlier in December, Giant Biogene Holding announced a share repurchase plan, following recent analyst coverage from Citic Securities, Citi and UBS. The buyback move is being read as a signal of management confidence and a direct attempt to enhance shareholder value. With the share repurchase plan now in place, we’ll explore how this capital allocation decision shapes Giant Biogene’s broader investment narrative. AI is about to change healthcare. These 30 stocks are working on everything...
SEHK:3690
SEHK:3690Hospitality

Is Meituan Finally a Bargain After a 37% Share Price Slump?

Wondering if Meituan is finally a bargain after years of volatility, or just another value trap in Chinese tech? This breakdown is designed to help you decide with a clear, valuation-led lens. The stock has inched up 2.2% over the last week even as it remains down 33.9% year to date and 37.3% over the past year, a combination that often signals shifting views on risk and long-term upside. Much of the recent movement has been shaped by ongoing headlines about China’s consumer recovery,...
SEHK:700
SEHK:700Interactive Media and Services

Is It Too Late To Consider Tencent After Its 2025 Rally And Valuation Upside?

If you are wondering whether Tencent Holdings is still attractive after its big run, or if you are arriving too late to benefit, this breakdown will help you consider whether the current price reflects the company’s long term potential. The stock has cooled off slightly in the short term, down 1.0% over the last week and 6.9% over the past month. It is still up 43.4% year to date and 49.5% over the past year, with a 108.0% gain over three years. These moves sit against a backdrop of...